Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK2186877A in Elderly Subjects
NCT00992784Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Primary completion
- May 2010
- Modality
- Whole Inactivated Vaccines
- Countries
- 3
01
Overview
Phase 3, single-blind trial of GSK2186877A in influenza (3 arms), sponsored by GSK. Primary endpoints: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events, Duration of Solicited Local AEs and 6 more. Started Oct 2009; status: completed.
02
Drugs
GSK2186877A
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00992784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992784.